The company maintains a conservative capital structure with a debt-to-equity ratio of 0.15 and a robust liquidity position of $245.6 million in cash as of 2026Q1.
| Total Current Assets | 428.03M | 450.38M | 481.84M | 350.57M | 272.63M | 326.17M | 109.9M | 50.36M |
| Cash & Short-Term Investments | 245.64M | 286.5M | 333.73M | 257.22M | 222.64M | 304.32M | 100.13M | 42.02M |
| Cash Only | 245.64M | 286.5M | 333.73M | 257.22M | 222.64M | 304.32M | 100.13M | 42.02M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 96.39M | 83.53M | 83.5M | 48.38M | 15.27M | 4.46M | 1.55M | 1.1M |
| Days Sales Outstanding | 97.83 | 98.97 | 135.75 | 129.65 | 74.31 | 47.26 | 73.26 | 65.02 |
| Inventory | 77.54M | 70.69M | 56.17M | 39.76M | 28.54M | 13.15M | 7.48M | 6.69M |
| Days Inventory Outstanding | 215.83 | 230.74 | 234.57 | 222.76 | 274.68 | 257.88 | 304.18 | 303 |
| Other Current Assets | 8.47M | 9.65M | 8.45M | 5.21M | 6.17M | 3.41M | 0 | 0 |
| Total Non-Current Assets | 59.03M | 57.7M | 52.17M | 54.15M | 36.7M | 10.85M | 16.07M | 11.64M |
| Property, Plant & Equipment | 48.9M | 47.94M | 45.65M | 48.99M | 32.14M | 8.32M | 12.91M | 8.27M |
| Fixed Asset Turnover | 6.72x | 6.43x | 4.92x | 2.78x | 2.33x | 4.14x | 0.60x | 0.75x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 640K | 709K | 932K | 1.2M | 1.48M | 1.75M | 2.02M | 2.29M |
| Long-Term Investments | 12.06M | 0 | 3.04M | 3.04M | 3.04M | 777K | 777K | 691K |
| Other Non-Current Assets | 9.49M | 9.06M | 2.56M | 919K | 51K | 0 | 356K | 378K |
| Total Assets | 487.06M | 508.08M | 534.02M | 404.72M | 309.33M | 337.02M | 125.97M | 61.99M |
| Asset Turnover | 0.64x | 0.61x | 0.42x | 0.34x | 0.24x | 0.10x | 0.06x | 0.10x |
| Asset Growth % | 62.7% | -4.86% | 31.95% | 30.84% | -8.22% | 167.54% | 103.2% | - |
| Total Current Liabilities | 63.64M | 65.8M | 53.13M | 45.93M | 35.29M | 16.24M | 14.53M | 6.79M |
| Accounts Payable | 18.85M | 17.29M | 10.03M | 13.5M | 9.39M | 2.03M | 1.24M | 1.44M |
| Days Payables Outstanding | 45.19 | 56.42 | 41.9 | 75.64 | 90.37 | 39.8 | 50.45 | 65.44 |
| Short-Term Debt | 0 | 0 | 1.91M | 1.68M | 2.13M | 2.1M | 6.26M | 0 |
| Deferred Revenue (Current) | 47.3M | 13.05M | 9.56M | 5.66M | 2.85M | 1.02M | 233K | 106K |
| Other Current Liabilities | 31.08M | 35.46M | 10.09M | 8.2M | 7.47M | 4.61M | 2.15M | 2.9M |
| Current Ratio | 6.73x | 6.85x | 9.07x | 7.63x | 7.73x | 20.08x | 7.57x | 7.42x |
| Quick Ratio | 5.51x | 5.77x | 8.01x | 6.77x | 6.92x | 19.27x | 7.05x | 6.43x |
| Cash Conversion Cycle | 268.47 | 273.3 | 328.43 | 276.77 | 258.61 | 265.35 | 327 | 302.59 |
| Total Non-Current Liabilities | 75.76M | 76.42M | 78.66M | 78.04M | 76.97M | 53.69M | 50.48M | 25.97M |
| Long-Term Debt | 51.66M | 51.62M | 51.47M | 51.34M | 51.21M | 50M | 44.41M | 23.22M |
| Capital Lease Obligations | 51.01M | 0 | 26.87M | 26.18M | 23.98M | 1.99M | 4.1M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 24.09M | 24.8M | 324K | 517K | 1.78M | 1.7M | 1.98M | 2.75M |
| Total Liabilities | 139.4M | 142.21M | 131.8M | 123.97M | 112.26M | 69.93M | 65.01M | 32.76M |
| Total Debt | 51.66M | 51.62M | 80.25M | 79.2M | 77.32M | 54.1M | 54.76M | 23.22M |
| Net Debt | -193.98M | -234.89M | -253.47M | -178.02M | -145.32M | -250.22M | -45.37M | -18.8M |
| Debt / Equity | 0.15x | 0.14x | 0.20x | 0.28x | 0.39x | 0.20x | 0.90x | 0.79x |
| Debt / EBITDA | -0.50x | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 1.89x | - | - | - | - | - | - | - |
| Interest Coverage | -30.92x | -28.96x | -20.85x | -25.51x | -15.82x | -9.30x | -9.08x | -56.98x |
| Total Equity | 347.67M | 365.87M | 402.22M | 280.75M | 197.07M | 267.09M | 60.96M | 29.23M |
| Equity Growth % | 91.18% | -9.04% | 43.27% | 42.46% | -26.22% | 338.14% | 108.55% | - |
| Book Value per Share | 6.15 | 6.59 | 7.72 | 5.94 | 4.44 | 6.11 | 1.73 | 0.87 |
| Total Shareholders' Equity | 347.67M | 365.87M | 402.22M | 280.75M | 197.07M | 267.09M | 60.96M | 29.23M |
| Common Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | -673.2M | -641.56M | -545.99M | -454.57M | -348.68M | -261.52M | -201.67M | -148.65M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 114K | 84K | -6K | -54K | -14K | 4K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Persistent cash burn trajectory
As reported in recent financial filings, PROCEPT BioRobotics has seen its total equity decline from $402.2 million in 2024Q4 to $347.7 million in 2026Q1, a trend that reflects the ongoing accumulation of net losses as the company prioritizes aggressive commercial expansion over immediate balance sheet preservation.
The contraction in equity suggests that the company is consuming its capital base to fund market penetration, which warrants close monitoring of the burn rate. Investors should consider whether the current pace of asset deployment will yield sufficient returns before the equity cushion requires further replenishment through dilutive financing.
Based on quarterly balance sheet data, the company maintains a conservative debt-to-equity ratio of 0.15 as of 2026Q1, indicating that management has avoided excessive reliance on external credit facilities while navigating the capital-intensive phase of its robotic platform rollout in the competitive urological device market.
The relatively low leverage profile suggests that the company retains significant financial flexibility to access debt markets if needed for future growth initiatives. However, the persistent negative retained earnings of $673.2 million imply that the business remains fundamentally dependent on equity-linked capital to sustain its current operating model.
According to recent SEC filings, the company holds $245.6 million in cash as of 2026Q1, providing a current ratio of 6.73, which suggests a robust short-term liquidity buffer that should adequately cover near-term operating expenses despite the ongoing cash burn associated with its commercial scaling efforts.
While the current ratio remains high, the downward trend from 9.07 in 2024Q4 indicates that liquidity is being utilized to support operations. This liquidity position appears sufficient for the immediate future, though the company's reliance on cash reserves to offset operating losses remains a primary point of analytical focus.
As reported in financial statements, the company's asset base is primarily composed of $48.9 million in net property, plant, and equipment as of 2026Q1, highlighting a business model that is heavily invested in the physical infrastructure required to support its specialized robotic surgical platform and manufacturing capabilities.
The relatively low level of goodwill, at $0.64 million, suggests that the company's asset valuation is grounded in tangible investments rather than historical acquisitions. This asset composition appears consistent with a company focused on organic growth and technological development within the medical device sector.
Based on the provided balance sheet data, deferred revenue has increased to $13.7 million in 2026Q1 from $5.7 million in 2023Q4, which may indicate a growing backlog of service contracts that will require future resource allocation to fulfill, potentially impacting long-term margin profiles for the company.
While rising deferred revenue is often a positive indicator of customer commitment, it also represents a future performance obligation that could constrain operational capacity. Analysts should monitor whether the cost to service these obligations aligns with the company's broader goals for achieving sustainable operating leverage.
Quick answers to the most common questions about buying PRCT stock.
As of 2025, PROCEPT BioRobotics Corporation (PRCT) had total assets of $508.1M including $450.4M in current assets.
PROCEPT BioRobotics Corporation (PRCT) carries total debt of $51.6M, offset by $286.5M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
PROCEPT BioRobotics Corporation (PRCT) has total shareholders' equity (book value) of $365.9M ($6.59 book value per share). Book value represents the net worth of the company belonging to common stock holders.
PROCEPT BioRobotics Corporation (PRCT) reported a current ratio of 6.85x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.